APA (7th ed.) Citation

San-Miguel, J. F., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., . . . Dimopoulos, M. (2013). Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. The lancet. Oncology, 14(11), . https://doi.org/10.1016/S1470-2045(13)70380-2

Chicago Style (17th ed.) Citation

San-Miguel, Jesús F., et al. "Pomalidomide Plus Low-dose Dexamethasone Versus High-dose Dexamethasone Alone for Patients with Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology 14, no. 11 (2013). https://doi.org/10.1016/S1470-2045(13)70380-2.

MLA (9th ed.) Citation

San-Miguel, Jesús F., et al. "Pomalidomide Plus Low-dose Dexamethasone Versus High-dose Dexamethasone Alone for Patients with Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-label, Phase 3 Trial." The Lancet. Oncology, vol. 14, no. 11, 2013, https://doi.org/10.1016/S1470-2045(13)70380-2.